Kamada Ltd. (NASDAQ:KMDA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm presently has a $6.00 price objective on the stock. Zacks Investment Research’s target price points to a potential upside of 12.15% from the company’s previous close.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

KMDA has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Kamada in a research report on Saturday, September 3rd. Jefferies Group restated a “buy” rating and set a $7.00 target price on shares of Kamada in a report on Wednesday, August 31st. Finally, TheStreet upgraded Kamada from a “sell” rating to a “hold” rating in a report on Monday, September 26th.

Kamada (NASDAQ:KMDA) opened at 5.35 on Tuesday. Kamada has a 52 week low of $3.26 and a 52 week high of $6.29. The company has a 50-day moving average price of $5.50 and a 200-day moving average price of $4.44. The stock’s market cap is $194.84 million.

An institutional investor recently raised its position in Kamada stock. Vanguard Group Inc. increased its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 19.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 327,533 shares of the company’s stock after buying an additional 52,195 shares during the period. Vanguard Group Inc. owned approximately 0.85% of Kamada worth $1,202,000 at the end of the most recent reporting period. Institutional investors own 5.31% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

5 Day Chart for NASDAQ:KMDA

Receive News & Stock Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related stocks with our FREE daily email newsletter.